NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners ...
MinervaX completed enrolment of its 2 nd phase II clinical trial of its novel GBS vaccine in pregnant women across Denmark, the UK and South Africa. The randomized, multicenter trial will evaluate the ...
BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market the BD MAX™ GBS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback